 <h1>Istalol Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>timolol ophthalmic</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about timolol ophthalmic. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Istalol.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to timolol ophthalmic: ophthalmic gel forming solution, ophthalmic solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, timolol ophthalmic (the active ingredient contained in Istalol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking timolol ophthalmic:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>burning or stinging in the eye</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Arm, back, or jaw pain</li>
<li>blisters, hives, welts, or itching</li>
<li>blue lips, fingernails, or skin</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>change in vision</li>
<li>chest pain or discomfort</li>
<li>chest tightness or heaviness</li>
<li>confusion about identity, place, and time</li>
<li>continuing ringing or buzzing or other unexplained noise in ears</li>
<li>coughing that sometimes produces a pink frothy sputum</li>
<li>depression</li>
<li>difficult, fast, noisy breathing</li>
<li>difficulty with chewing, swallowing, or talking</li>
<li>dilated neck veins</li>
<li>discharge, excessive tearing</li>
<li>disturbed color perception</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>double vision</li>
<li>drooping eyelids</li>
<li>dry or itching eyes</li>
<li>extreme fatigue</li>
<li>false sense of well-being</li>
<li>fast, slow, irregular, pounding, or racing heartbeat or pulse</li>
<li>fear or nervousness</li>
<li>feeling of having something in the eye</li>
<li>fever and chills</li>
<li>flashes of light, floaters in vision</li>
<li>general feeling of discomfort or illness</li>
<li>hair loss</li>
<li>halos around lights</li>
<li>headache</li>
<li>inability to speak</li>
<li>increased sweating</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>loss of vision</li>
<li>memory loss</li>
<li>mood swings</li>
<li>muscle or joint pain</li>
<li>muscle weakness</li>
<li>nausea</li>
<li>night blindness</li>
<li>no blood pressure or pulse</li>
<li>overbright appearance of lights</li>
<li>pain, tension, and weakness upon walking that subsides during periods of rest</li>
<li>pale skin</li>
<li>paleness or cold feeling in the fingertips, toes, hands, and feet</li>
<li>personality changes</li>
<li>pounding in the ears</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>redness of the skin</li>
<li>redness, pain, swelling or irritation of the eye, eyelid, or inner lining of the eyelid</li>
<li>seeing double</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>seizures</li>
<li>severe numbness, especially on one side of the face or body</li>
<li>severe or sudden headache</li>
<li>severe tiredness</li>
<li>skin irritation or rash, including rash that looks like psoriasis</li>
<li>slurred speech</li>
<li>sore throat</li>
<li>stopping of heart</li>
<li>sweating</li>
<li>swelling of the face, fingers, feet, lower legs, and ankles</li>
<li>swollen glands</li>
<li>temporary blindness</li>
<li>tingling or pain in the fingers or toes when exposed to cold</li>
<li>tunnel vision</li>
<li>unconsciousness</li>
<li>unusual tiredness or weakness</li>
<li>weakness in arm and/or leg on one side of the body, sudden and severe</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of timolol ophthalmic may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>body aches or pain</li>
<li>diarrhea</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>hearing loss</li>
<li>heartburn</li>
<li>indigestion</li>
<li>lack or loss of strength</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>nightmares</li>
<li>runny nose</li>
<li>sleepiness or unusual drowsiness</li>
<li>sneezing</li>
<li>stomach discomfort, upset, or pain</li>
<li>stuffy nose</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<!-- end ophthalmic gel forming solution, ophthalmic solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to timolol ophthalmic: ophthalmic gel forming solution, ophthalmic solution</i></p><h3>General</h3><p>Gel-forming Solution: The most commonly reported side effects were transient blurred vision, burning, and stinging.</p>
<p></p>
<p>Long-acting Solution: The most commonly reported side effects included burning and stinging on administration.</p>
<p></p>
<p>Ophthalmic Solution: The most commonly reported side effects included localized burning and stinging.<sup>[Ref]</sup></p><h3>Local</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Burning, itching, localized rash, redness, signs/symptoms of ocular irritation, stinging, tearing</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Very common</b> (10% or more): Burning (up to 12.5%), stinging (up to 12.5%)</p>
<p><b>Common</b> (1% to 10%): Crusting, discharge, itching, pain</p>
<p><b>Frequency not reported</b>: local weakness, localized rash, signs/symptoms of ocular irritation</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Very common</b> (10% or more): Burning (up to 38%), stinging (up to 38%)</p>
<p><b>Common</b> (1% to 10%): Itching</p>
<p><b>Frequency not reported</b>: Crusting, discharge, localized rash, signs/symptoms of ocular irritation</p>
<p><b>Postmarketing reports</b>: Local weakness</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Very common</b> (10% or more): Biting sensation (up to 13%), burning sensation (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Itching, secretion, signs/symptoms of ocular irritation, stinging</p>
<p><b>Rare</b> (0.01% to 0.1%): Localized rash</p>
<p><b>Frequency not reported</b>: Local weakness<sup>[Ref]</sup></p><h3>Ocular</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Blepharitis, blurred vision, choroidal detachment (following filtration surgery), conjunctival hyperemia, conjunctivitis, corneal erosion, decreased corneal sensitivity, dry eyes, keratitis, refractive changes</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Very common</b> (10% or more): Transient blurred vision (up to 33%)</p>
<p><b>Common</b> (1% to 10%): Blurred vision, conjunctival injection, conjunctivitis, foreign body sensation, tearing</p>
<p><b>Frequency not reported</b>: Blepharitis, choroidal detachment (following filtration surgery) corneal erosion, cystoid macular edema, decreased corneal sensitivity, dry eyes, keratitis, redness, refractive changes, visual disturbances</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Common</b> (1% to 10%): Blurred vision, cataract, conjunctival injection, decreased visual acuity</p>
<p><b>Frequency not reported</b>: Blepharitis, choroidal detachment (following filtration surgery), conjunctivitis, cystoid macular edema, decreased corneal sensitivity, dry eyes, foreign body sensation, keratitis, ocular pain, refractive changes, tearing, visual disturbances</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Abnormal vision, blepharitis, blurred vision, cataract, conjunctival hyperemia, conjunctival injection, conjunctivitis, corneal fluorescein staining, decreased corneal sensitivity, dry eyes, epiphora, eye discomfort, eye pain, eyelid erythema, foreign body sensation, keratitis, photophobia</p>
<p><b>Rare</b> (0.01% to 0.1%): Refractive changes, visual disturbance</p>
<p><b>Frequency not reported</b>: Aphakic cystoid macular edema, choroidal detachment (following filtration surgery), corneal calcification, corneal erosion, crusting, cystoid macular edema, discharge, ocular pain, redness, retinal vascular disorder, tearing<sup>[Ref]</sup></p><p>In some patients, refractive changes occurred as a result of mitotic therapy withdrawal.</p>
<p></p>
<p>Corneal calcification occurred with phosphate-containing drops in patients with significantly damaged corneas.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Arrhythmia, atrioventricular (AV) block, bradycardia, cardiac arrest, cardiac failure, chest pain, claudication, cold hands and feet, congestive heart failure, edema, hypotension, palpitations, Raynaud's phenomenon</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Arrhythmia, bradycardia, cardiac arrest, cardiac failure, chest pain, claudication, cold hands and feet, congestive heart failure, edema, heart block, hypertension, hypotension, palpitation, Raynaud's phenomenon, second-/third-degree AV block, sinoatrial block, vasodilation, worsening of angina pectoris, worsening of arterial insufficiency</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Frequency not reported</b>: Arrhythmia, bradycardia, cardiac arrest, cardiac failure, chest pain, claudication, cold hands and feet, edema, heart block, hypotension, palpitation, Raynaud's phenomenon, worsening of angina pectoris</p>
<p><b>Postmarketing reports</b>: Vasodilation, worsening of arterial insufficiency</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Hypertension, peripheral edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Bradycardia</p>
<p><b>Rare</b> (0.01% to 0.1%): Arrhythmia, cardiac arrest, chest pain, claudication, cold hands and feet, congestive heart failure, edema, heart block, hypotension, palpitation, Raynaud's phenomenon</p>
<p><b>Frequency not reported</b>: Cardiac failure, second-/third-degree AV block, sinoatrial block, vasodilation, worsening of angina pectoris, worsening of arterial insufficiency<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Cerebral ischemia, cerebrovascular accident, diplopia, dizziness, dysgeusia, headache, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis, syncope</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Common</b> (1% to 10%): Dizziness, headache</p>
<p><b>Frequency not reported</b>: Cerebral ischemia, cerebrovascular accident, diplopia, dysgeusia, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis, slightly clouded sensorium, somnolence, syncope, vertigo</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Frequency not reported</b>: Cerebral ischemia, cerebrovascular accident, diplopia, dizziness, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis, somnolence, syncope</p>
<p><b>Postmarketing reports</b>: Slightly clouded sensorium, vertigo</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Dizziness, headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Syncope</p>
<p><b>Rare</b> (0.01% to 0.1%): Cerebral ischemia, cerebrovascular accident, diplopia, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis</p>
<p><b>Frequency not reported</b>: Blepharoptosis, central nervous system (CNS) effects, dysgeusia, increased dreaming, slightly clouded sensorium, somnolence, syncope, vertigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Bronchospasm, cough, dyspnea</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Common</b> (1% to 10%): Upper respiratory infections</p>
<p><b>Frequency not reported</b>: Asthma exacerbation, bronchial obstruction, bronchospasm, cough, dyspnea, laryngospasm with respiratory distress, nasal congestion, pulmonary edema, rales, respiratory failure</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Bronchospasm, cough, dyspnea, nasal congestion, pulmonary edema, respiratory failure, upper respiratory infections</p>
<p><b>Postmarketing reports</b>: Bronchial obstruction, laryngospasm with respiratory distress, rales</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Respiratory infection, sinusitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p>
<p><b>Rare</b> (0.01% to 0.1%): Bronchospasm, cough, respiratory failure</p>
<p><b>Frequency not reported</b>: Asthma exacerbation, bronchial obstruction, laryngospasm with respiratory distress, nasal congestion, pulmonary edema, rales, upper respiratory infections<sup>[Ref]</sup></p><p>Bronchospasm most commonly occurred in patients with preexisting bronchospastic disease.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Abdominal pain, diarrhea, dry mouth, dyspepsia, nausea, vomiting</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Abdominal pain, diarrhea, dry mouth, dyspepsia, ischemic colitis, mesenteric arterial thrombosis, nausea, vomiting</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Diarrhea, dry mouth, dyspepsia, nausea</p>
<p><b>Postmarketing reports</b>: Gastrointestinal pain, ischemic colitis, mesenteric arterial thrombosis, vomiting</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Dry mouth, nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspepsia</p>
<p><b>Rare</b> (0.01% to 0.1%): Diarrhea</p>
<p><b>Frequency not reported</b>: Abdominal pain, gastrointestinal pain, ischemic colitis, mesenteric arterial thrombosis, vomiting<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Antinuclear antibodies positive, psoriasis exacerbation</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Psoriasis exacerbation, retroperitoneal fibrosis</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Common</b> (1% to 10%): Infection</p>
<p><b>Frequency not reported</b>: Psoriasis exacerbation, retroperitoneal fibrosis</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Common cold</p>
<p><b>Rare</b> (0.01% to 0.1%): Psoriasis exacerbation</p>
<p><b>Frequency not reported</b>: Retroperitoneal fibrosis<sup>[Ref]</sup></p><h3>Other</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Asthenia, fatigue</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Asthenia, decreased exercise tolerance, fatigue, fever combined with aching and sore throat, tinnitus</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Asthenia, fatigue</p>
<p><b>Postmarketing reports</b>: Decreased exercise tolerance, fever combined with aching and sore throat</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Fatigue</p>
<p><b>Rare</b> (0.01% to 0.1%): Tinnitus</p>
<p><b>Frequency not reported</b>: Decreased exercise tolerance, fever with aching and sore throat<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Anaphylactic reaction, angioedema, systemic allergic reactions</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Anaphylactic reaction, anaphylaxis, angioedema, exfoliative dermatitis, signs/symptoms of allergic reactions</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Angioedema, signs/symptoms of systemic allergic reactions</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Allergic reaction</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis, angioedema, signs/symptoms of allergic reactions</p>
<p><b>Frequency not reported</b>: Exfoliative dermatitis, hypersensitivity, signs/symptoms of systemic allergic reactions, systemic allergic reactions<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Decreased libido, depression, hallucination, insomnia, nightmares</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Acute reversible syndrome characterized by disorientation to time/place, anxiety, behavioral changes, confusion, decreased libido, decreased performance on neuropsychometrics, depression, diminished concentration, disorientation, emotional lability, hallucinations, increased dreaming, insomnia, nervousness, nightmares, psychic disturbances, reversible mental depression progressing to catatonia</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Anxiety, behavioral changes, confusion, decreased libido, depression, disorientation, hallucinations, insomnia, nervousness, nightmares, psychic disturbances</p>
<p><b>Postmarketing reports</b>: Acute reversible syndrome characterized by disorientation for time and place, decreased performance on neuropsychometrics, diminished concentration, emotional lability, reversible mental depression progression to catatonia</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Uncommon</b> (0.1% to 1%): Depression</p>
<p><b>Rare</b> (0.01% to 0.1%): Decreased libido, insomnia, nightmares</p>
<p><b>Frequency not reported</b>: Acute reversible syndrome characterized by disorientation for time and place, anxiety, behavioral changes, confusion, decreased/diminished concentration, decreased performance on neuropsychometrics, disorientation, emotional lability, hallucinations, nervousness, psychic disturbances, reversible mental depression progressing to catatonia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Myalgia, systemic lupus erythematosus</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Arthralgia, extremity pain, myalgia, systemic lupus erythematosus</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Systemic lupus erythematosus</p>
<p><b>Postmarketing reports</b>: Arthralgia, extremity pain</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Common</b> (1% to 10%): Extremity pain</p>
<p><b>Rare</b> (0.01% to 0.1%): Systemic lupus erythematosus</p>
<p><b>Frequency not reported</b>: Arthralgia, myalgia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Alopecia, generalized rash, pruritus, psoriasiform rash, skin rash, urticaria</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Alopecia, erythematous rash, generalized rash, increased pigmentation, nonthrombocytopenic purpura, pruritus, pseudopemphigoid, psoriasiform rash, skin irritation, skin rash, sweating, thrombocytopenic purpura, urticaria</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Alopecia, generalized rash, pseudopemphigoid, psoriasiform rash, urticaria</p>
<p><b>Postmarketing reports</b>: Erythematous rash, increased pigmentation, nonthrombocytopenic purpura, pruritus, skin irritation, sweating, thrombocytopenic purpura</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Rare</b> (0.01% to 0.1%): Alopecia, generalized rash, psoriasiform rash, urticaria</p>
<p><b>Frequency not reported</b>: Erythematous rash, increased pigmentation, nonthrombocytopenic purpura, pruritus, pseudopemphigoid, skin irritation, skin rash, sweating, thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Impotence, sexual dysfunction</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Impotence, micturition/urination difficulties, Peyronie's disease, sexual dysfunction</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Impotence, Peyronie's disease</p>
<p><b>Postmarketing reports</b>: Urination difficulties</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Rare</b> (0.01% to 0.1%): Peyronie's disease</p>
<p><b>Frequency not reported</b>: Impotence, micturition difficulty, sexual dysfunction, urinary difficulties<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Gel:</p>
<p><b>Frequency not reported</b>: Hypoglycemia</p>
<p></p>
<p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Anorexia, high-density lipoprotein (HDL)-cholesterol slightly decreased, hyperglycemia, hypoglycemia, masked symptoms of hypoglycemia, serum potassium slightly increased, serum triglycerides slightly increased, serum uric acid slightly increased, weight loss</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Frequency not reported</b>: Anorexia, masked symptoms of hypoglycemia</p>
<p><b>Postmarketing reports</b>: Hyperglycemia, hypoglycemia, weight loss</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Frequency not reported</b>: Anorexia, HDL-cholesterol slightly decreased, hyperglycemia, hypoglycemia, masked symptoms of hypoglycemia, serum potassium increased, serum triglycerides increased, serum uric acid increased, weight loss<sup>[Ref]</sup></p><p>Masked hypoglycemia symptoms occurred in patients with diabetes.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Agranulocytosis, hematocrit slightly decreased, hemoglobin slightly decreased</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Postmarketing reports</b>: Agranulocytosis</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Frequency not reported</b>: Agranulocytosis, hematocrit slightly decreased, hemoglobin slightly decreased<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Hepatomegaly</p>
<p></p>
<p>Long-acting Solution:</p>
<p><b>Postmarketing reports</b>: Hepatomegaly</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Frequency not reported</b>: Hepatomegaly<sup>[Ref]</sup></p><h3>Renal</h3><p>Gel-forming Solution:</p>
<p><b>Frequency not reported</b>: Serum urea slightly increased</p>
<p></p>
<p>Ophthalmic Solution:</p>
<p><b>Frequency not reported</b>: Increased blood urea nitrogen (BUN)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Timolol Maleate, Ophthalmic (timolol ophthalmic)." Bausch and Lomb, Rochester, NY. </p><p id="ref_2">2. "Product Information. Timoptic (timolol ophthalmic)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Istalol (timolol ophthalmic)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: ophthalmic glaucoma agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Istalol &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Timoptic, Betimol, Timoptic Ocudose, Timoptic-XE</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Glaucoma, Open Angle</li>
<li>Intraocular Hypertension</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to timolol ophthalmic: ophthalmic gel forming solution, ophthalmic solution</i></p><h3>General</h3><p>Gel-forming Solution: The most commonly reported side effects were transient blurred vision, burning, and stinging.</p><p></p><p>Long-acting Solution: The most commonly reported side effects included burning and stinging on administration.</p><p></p><p>Ophthalmic Solution: The most commonly reported side effects included localized burning and stinging.<sup>[Ref]</sup></p><h3>Local</h3><p>Gel:</p><p><b>Frequency not reported</b>: Burning, itching, localized rash, redness, signs/symptoms of ocular irritation, stinging, tearing</p><p></p><p>Gel-forming Solution:</p><p><b>Very common</b> (10% or more): Burning (up to 12.5%), stinging (up to 12.5%)</p><p><b>Common</b> (1% to 10%): Crusting, discharge, itching, pain</p><p><b>Frequency not reported</b>: local weakness, localized rash, signs/symptoms of ocular irritation</p><p></p><p>Long-acting Solution:</p><p><b>Very common</b> (10% or more): Burning (up to 38%), stinging (up to 38%)</p><p><b>Common</b> (1% to 10%): Itching</p><p><b>Frequency not reported</b>: Crusting, discharge, localized rash, signs/symptoms of ocular irritation</p><p><b>Postmarketing reports</b>: Local weakness</p><p></p><p>Ophthalmic Solution:</p><p><b>Very common</b> (10% or more): Biting sensation (up to 13%), burning sensation (up to 13%)</p><p><b>Common</b> (1% to 10%): Itching, secretion, signs/symptoms of ocular irritation, stinging</p><p><b>Rare</b> (0.01% to 0.1%): Localized rash</p><p><b>Frequency not reported</b>: Local weakness<sup>[Ref]</sup></p><h3>Ocular</h3><p>Gel:</p><p><b>Frequency not reported</b>: Blepharitis, blurred vision, choroidal detachment (following filtration surgery), conjunctival hyperemia, conjunctivitis, corneal erosion, decreased corneal sensitivity, dry eyes, keratitis, refractive changes</p><p></p><p>Gel-forming Solution:</p><p><b>Very common</b> (10% or more): Transient blurred vision (up to 33%)</p><p><b>Common</b> (1% to 10%): Blurred vision, conjunctival injection, conjunctivitis, foreign body sensation, tearing</p><p><b>Frequency not reported</b>: Blepharitis, choroidal detachment (following filtration surgery) corneal erosion, cystoid macular edema, decreased corneal sensitivity, dry eyes, keratitis, redness, refractive changes, visual disturbances</p><p></p><p>Long-acting Solution:</p><p><b>Common</b> (1% to 10%): Blurred vision, cataract, conjunctival injection, decreased visual acuity</p><p><b>Frequency not reported</b>: Blepharitis, choroidal detachment (following filtration surgery), conjunctivitis, cystoid macular edema, decreased corneal sensitivity, dry eyes, foreign body sensation, keratitis, ocular pain, refractive changes, tearing, visual disturbances</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Abnormal vision, blepharitis, blurred vision, cataract, conjunctival hyperemia, conjunctival injection, conjunctivitis, corneal fluorescein staining, decreased corneal sensitivity, dry eyes, epiphora, eye discomfort, eye pain, eyelid erythema, foreign body sensation, keratitis, photophobia</p><p><b>Rare</b> (0.01% to 0.1%): Refractive changes, visual disturbance</p><p><b>Frequency not reported</b>: Aphakic cystoid macular edema, choroidal detachment (following filtration surgery), corneal calcification, corneal erosion, crusting, cystoid macular edema, discharge, ocular pain, redness, retinal vascular disorder, tearing<sup>[Ref]</sup></p><p>In some patients, refractive changes occurred as a result of mitotic therapy withdrawal.</p><p></p><p>Corneal calcification occurred with phosphate-containing drops in patients with significantly damaged corneas.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Gel:</p><p><b>Frequency not reported</b>: Arrhythmia, atrioventricular (AV) block, bradycardia, cardiac arrest, cardiac failure, chest pain, claudication, cold hands and feet, congestive heart failure, edema, hypotension, palpitations, Raynaud's phenomenon</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Arrhythmia, bradycardia, cardiac arrest, cardiac failure, chest pain, claudication, cold hands and feet, congestive heart failure, edema, heart block, hypertension, hypotension, palpitation, Raynaud's phenomenon, second-/third-degree AV block, sinoatrial block, vasodilation, worsening of angina pectoris, worsening of arterial insufficiency</p><p></p><p>Long-acting Solution:</p><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Frequency not reported</b>: Arrhythmia, bradycardia, cardiac arrest, cardiac failure, chest pain, claudication, cold hands and feet, edema, heart block, hypotension, palpitation, Raynaud's phenomenon, worsening of angina pectoris</p><p><b>Postmarketing reports</b>: Vasodilation, worsening of arterial insufficiency</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Hypertension, peripheral edema</p><p><b>Uncommon</b> (0.1% to 1%): Bradycardia</p><p><b>Rare</b> (0.01% to 0.1%): Arrhythmia, cardiac arrest, chest pain, claudication, cold hands and feet, congestive heart failure, edema, heart block, hypotension, palpitation, Raynaud's phenomenon</p><p><b>Frequency not reported</b>: Cardiac failure, second-/third-degree AV block, sinoatrial block, vasodilation, worsening of angina pectoris, worsening of arterial insufficiency<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Gel:</p><p><b>Frequency not reported</b>: Cerebral ischemia, cerebrovascular accident, diplopia, dizziness, dysgeusia, headache, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis, syncope</p><p></p><p>Gel-forming Solution:</p><p><b>Common</b> (1% to 10%): Dizziness, headache</p><p><b>Frequency not reported</b>: Cerebral ischemia, cerebrovascular accident, diplopia, dysgeusia, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis, slightly clouded sensorium, somnolence, syncope, vertigo</p><p></p><p>Long-acting Solution:</p><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Cerebral ischemia, cerebrovascular accident, diplopia, dizziness, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis, somnolence, syncope</p><p><b>Postmarketing reports</b>: Slightly clouded sensorium, vertigo</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Dizziness, headache</p><p><b>Uncommon</b> (0.1% to 1%): Syncope</p><p><b>Rare</b> (0.01% to 0.1%): Cerebral ischemia, cerebrovascular accident, diplopia, increase in signs/symptoms of myasthenia gravis, memory loss, paresthesia, ptosis</p><p><b>Frequency not reported</b>: Blepharoptosis, central nervous system (CNS) effects, dysgeusia, increased dreaming, slightly clouded sensorium, somnolence, syncope, vertigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Gel:</p><p><b>Frequency not reported</b>: Bronchospasm, cough, dyspnea</p><p></p><p>Gel-forming Solution:</p><p><b>Common</b> (1% to 10%): Upper respiratory infections</p><p><b>Frequency not reported</b>: Asthma exacerbation, bronchial obstruction, bronchospasm, cough, dyspnea, laryngospasm with respiratory distress, nasal congestion, pulmonary edema, rales, respiratory failure</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Bronchospasm, cough, dyspnea, nasal congestion, pulmonary edema, respiratory failure, upper respiratory infections</p><p><b>Postmarketing reports</b>: Bronchial obstruction, laryngospasm with respiratory distress, rales</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Respiratory infection, sinusitis</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p><p><b>Rare</b> (0.01% to 0.1%): Bronchospasm, cough, respiratory failure</p><p><b>Frequency not reported</b>: Asthma exacerbation, bronchial obstruction, laryngospasm with respiratory distress, nasal congestion, pulmonary edema, rales, upper respiratory infections<sup>[Ref]</sup></p><p>Bronchospasm most commonly occurred in patients with preexisting bronchospastic disease.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gel:</p><p><b>Frequency not reported</b>: Abdominal pain, diarrhea, dry mouth, dyspepsia, nausea, vomiting</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Abdominal pain, diarrhea, dry mouth, dyspepsia, ischemic colitis, mesenteric arterial thrombosis, nausea, vomiting</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Diarrhea, dry mouth, dyspepsia, nausea</p><p><b>Postmarketing reports</b>: Gastrointestinal pain, ischemic colitis, mesenteric arterial thrombosis, vomiting</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Dry mouth, nausea</p><p><b>Uncommon</b> (0.1% to 1%): Dyspepsia</p><p><b>Rare</b> (0.01% to 0.1%): Diarrhea</p><p><b>Frequency not reported</b>: Abdominal pain, gastrointestinal pain, ischemic colitis, mesenteric arterial thrombosis, vomiting<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Gel:</p><p><b>Frequency not reported</b>: Antinuclear antibodies positive, psoriasis exacerbation</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Psoriasis exacerbation, retroperitoneal fibrosis</p><p></p><p>Long-acting Solution:</p><p><b>Common</b> (1% to 10%): Infection</p><p><b>Frequency not reported</b>: Psoriasis exacerbation, retroperitoneal fibrosis</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Common cold</p><p><b>Rare</b> (0.01% to 0.1%): Psoriasis exacerbation</p><p><b>Frequency not reported</b>: Retroperitoneal fibrosis<sup>[Ref]</sup></p><h3>Other</h3><p>Gel:</p><p><b>Frequency not reported</b>: Asthenia, fatigue</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Asthenia, decreased exercise tolerance, fatigue, fever combined with aching and sore throat, tinnitus</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Asthenia, fatigue</p><p><b>Postmarketing reports</b>: Decreased exercise tolerance, fever combined with aching and sore throat</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Asthenia</p><p><b>Uncommon</b> (0.1% to 1%): Fatigue</p><p><b>Rare</b> (0.01% to 0.1%): Tinnitus</p><p><b>Frequency not reported</b>: Decreased exercise tolerance, fever with aching and sore throat<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Gel:</p><p><b>Frequency not reported</b>: Anaphylactic reaction, angioedema, systemic allergic reactions</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Anaphylactic reaction, anaphylaxis, angioedema, exfoliative dermatitis, signs/symptoms of allergic reactions</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Angioedema, signs/symptoms of systemic allergic reactions</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Allergic reaction</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis, angioedema, signs/symptoms of allergic reactions</p><p><b>Frequency not reported</b>: Exfoliative dermatitis, hypersensitivity, signs/symptoms of systemic allergic reactions, systemic allergic reactions<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Gel:</p><p><b>Frequency not reported</b>: Decreased libido, depression, hallucination, insomnia, nightmares</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Acute reversible syndrome characterized by disorientation to time/place, anxiety, behavioral changes, confusion, decreased libido, decreased performance on neuropsychometrics, depression, diminished concentration, disorientation, emotional lability, hallucinations, increased dreaming, insomnia, nervousness, nightmares, psychic disturbances, reversible mental depression progressing to catatonia</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Anxiety, behavioral changes, confusion, decreased libido, depression, disorientation, hallucinations, insomnia, nervousness, nightmares, psychic disturbances</p><p><b>Postmarketing reports</b>: Acute reversible syndrome characterized by disorientation for time and place, decreased performance on neuropsychometrics, diminished concentration, emotional lability, reversible mental depression progression to catatonia</p><p></p><p>Ophthalmic Solution:</p><p><b>Uncommon</b> (0.1% to 1%): Depression</p><p><b>Rare</b> (0.01% to 0.1%): Decreased libido, insomnia, nightmares</p><p><b>Frequency not reported</b>: Acute reversible syndrome characterized by disorientation for time and place, anxiety, behavioral changes, confusion, decreased/diminished concentration, decreased performance on neuropsychometrics, disorientation, emotional lability, hallucinations, nervousness, psychic disturbances, reversible mental depression progressing to catatonia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Gel:</p><p><b>Frequency not reported</b>: Myalgia, systemic lupus erythematosus</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Arthralgia, extremity pain, myalgia, systemic lupus erythematosus</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Systemic lupus erythematosus</p><p><b>Postmarketing reports</b>: Arthralgia, extremity pain</p><p></p><p>Ophthalmic Solution:</p><p><b>Common</b> (1% to 10%): Extremity pain</p><p><b>Rare</b> (0.01% to 0.1%): Systemic lupus erythematosus</p><p><b>Frequency not reported</b>: Arthralgia, myalgia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Gel:</p><p><b>Frequency not reported</b>: Alopecia, generalized rash, pruritus, psoriasiform rash, skin rash, urticaria</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Alopecia, erythematous rash, generalized rash, increased pigmentation, nonthrombocytopenic purpura, pruritus, pseudopemphigoid, psoriasiform rash, skin irritation, skin rash, sweating, thrombocytopenic purpura, urticaria</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Alopecia, generalized rash, pseudopemphigoid, psoriasiform rash, urticaria</p><p><b>Postmarketing reports</b>: Erythematous rash, increased pigmentation, nonthrombocytopenic purpura, pruritus, skin irritation, sweating, thrombocytopenic purpura</p><p></p><p>Ophthalmic Solution:</p><p><b>Rare</b> (0.01% to 0.1%): Alopecia, generalized rash, psoriasiform rash, urticaria</p><p><b>Frequency not reported</b>: Erythematous rash, increased pigmentation, nonthrombocytopenic purpura, pruritus, pseudopemphigoid, skin irritation, skin rash, sweating, thrombocytopenic purpura<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Gel:</p><p><b>Frequency not reported</b>: Impotence, sexual dysfunction</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Impotence, micturition/urination difficulties, Peyronie's disease, sexual dysfunction</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Impotence, Peyronie's disease</p><p><b>Postmarketing reports</b>: Urination difficulties</p><p></p><p>Ophthalmic Solution:</p><p><b>Rare</b> (0.01% to 0.1%): Peyronie's disease</p><p><b>Frequency not reported</b>: Impotence, micturition difficulty, sexual dysfunction, urinary difficulties<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Gel:</p><p><b>Frequency not reported</b>: Hypoglycemia</p><p></p><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Anorexia, high-density lipoprotein (HDL)-cholesterol slightly decreased, hyperglycemia, hypoglycemia, masked symptoms of hypoglycemia, serum potassium slightly increased, serum triglycerides slightly increased, serum uric acid slightly increased, weight loss</p><p></p><p>Long-acting Solution:</p><p><b>Frequency not reported</b>: Anorexia, masked symptoms of hypoglycemia</p><p><b>Postmarketing reports</b>: Hyperglycemia, hypoglycemia, weight loss</p><p></p><p>Ophthalmic Solution:</p><p><b>Frequency not reported</b>: Anorexia, HDL-cholesterol slightly decreased, hyperglycemia, hypoglycemia, masked symptoms of hypoglycemia, serum potassium increased, serum triglycerides increased, serum uric acid increased, weight loss<sup>[Ref]</sup></p><p>Masked hypoglycemia symptoms occurred in patients with diabetes.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Agranulocytosis, hematocrit slightly decreased, hemoglobin slightly decreased</p><p></p><p>Long-acting Solution:</p><p><b>Postmarketing reports</b>: Agranulocytosis</p><p></p><p>Ophthalmic Solution:</p><p><b>Frequency not reported</b>: Agranulocytosis, hematocrit slightly decreased, hemoglobin slightly decreased<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Hepatomegaly</p><p></p><p>Long-acting Solution:</p><p><b>Postmarketing reports</b>: Hepatomegaly</p><p></p><p>Ophthalmic Solution:</p><p><b>Frequency not reported</b>: Hepatomegaly<sup>[Ref]</sup></p><h3>Renal</h3><p>Gel-forming Solution:</p><p><b>Frequency not reported</b>: Serum urea slightly increased</p><p></p><p>Ophthalmic Solution:</p><p><b>Frequency not reported</b>: Increased blood urea nitrogen (BUN)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Timolol Maleate, Ophthalmic (timolol ophthalmic)." Bausch and Lomb, Rochester, NY. </p><p id="ref_2">2. "Product Information. Timoptic (timolol ophthalmic)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about Istalol (timolol ophthalmic)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: ophthalmic glaucoma agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Istalol &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Glaucoma, Open Angle</li>
<li>Intraocular Hypertension</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>